What Interpharma does

Interpharma is the industry association (Verein) of research-based pharmaceutical companies in Switzerland, founded in 1933 and headquartered in Basel. The organization represents 25 member companies — including Roche, Novartis, Johnson & Johnson, Pfizer, Bristol Myers Squibb, Eli Lilly, AbbVie, AstraZeneca, Moderna, and Takeda — which collectively operate 47 sites across Switzerland and employ nearly 40,000 people, including approximately 900 apprentices. Interpharma does not develop products or technology in the conventional commercial sense; instead it operates a portfolio of information products including the Jahresbericht (annual report), Innovationsreport, Panorama Gesundheit, and the Pharmastandort Schweiz economic analyses, alongside educational platforms such as biotechlerncenter and the Bio-App, a Datacenter industry statistics portal, dialogue forums (Salon Santé), and political campaigns such as #WirForschenWeiter and "Medizin bewegt unser Leben."

The organization's revenue model is membership dues, with no commercial pricing or licensing of products. Its go-to-market motion is community-led advocacy and public affairs: conducting and publishing the annual Europa poll with gfs.bern, organizing the Pharmaceutical Industry Day conference, running press campaigns and member-driven policy briefs on healthcare, regulation, and trade, and engaging in direct advocacy on pricing, market access, and bilateral agreements. Operating geographies are concentrated in Switzerland (Europe), with stakeholder engagement extending into EMEA. Geographic and segment constraints are tied to the Swiss federal political and regulatory arena rather than commercial markets.

Strategically, Interpharma's core function is collective representation on issues affecting Switzerland's pharmaceutical industry: opposition to U.S. pharmaceutical tariffs and Section 301 trade investigations, advocacy for Bilateral III agreements with the EU, defense of strong intellectual property standards in FTAs such as with Mercosur, and policy work on Swiss drug pricing, market access, and innovation incentives. In 2026 the association underwent a board refresh, adding new members from J&J, AbbVie, BMS, Eli Lilly, and Pfizer, while continuing CEO René P. Buholzer's leadership. Financial funding flows solely from member company dues, with no disclosed external investment, parent company, or commercial revenue streams.

Name

Interpharma

Legal name

Interpharma, Verband der forschenden Pharmaunternehmen der Schweiz

Website

https://interpharma.ch

Company type

Private

Founded year

1933

Operating status

Operating

Headcount range

11–50 employees

Short description

Interpharma is the Swiss industry association (founded 1933, Basel) representing 25 research-based pharmaceutical companies operating in Switzerland. It conducts policy advocacy, market access campaigns, and industry reporting on trade, pricing, and innovation for the pharma sector.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Association

NAICS

Public Relations Agencies (541820)

SIC

International Affairs (9721)

akta.pro primary industry

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)

akta.pro secondary industry

Global Supply Chain, Procurement & Market-Shaping Partnerships (Medicines/Diagnostics/Vaccines) (HLAJAOAK)

Keywords

• Pharmaceutical industry association
• Pharma policy advocacy
• Biomedical research promotion
• Pharma market access
• Healthcare policy representation

Headquarters

HQ city

Basle

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Membership dues: Interpharma is funded by membership dues from its member pharmaceutical companies. It does not generate commercial revenue from products or services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Interpharma is the association of research-based pharmaceutical companies in Switzerland, founded in 1933 as a Verein with headquarters in Basel. It represents approximately 25 major pharmaceutical companies operating at 47 sites across Switzerland, providing industry advocacy, healthcare policy representation, public communications, and data-driven publications. Its core activities include political campaigns on EU bilateral agreements and U.S. tariff issues, an annual Europa public opinion poll, the Pharmaceutical Industry Day conference, the Salon Santé dialogue platform, and industry research and publications.

Product overview

Interpharma is the association of Switzerland's research-based pharmaceutical companies, established in 1933 and headquartered in Basel. Rather than offering a unified product platform, Interpharma serves as a policy, advocacy, and information hub for the Swiss pharmaceutical industry. Its portfolio includes annual publications (Jahresbericht, Innovationsreport), educational platforms (biotechlerncenter, Bio-App), a data portal (Datacenter), and communication services (Newsletter). The association also runs advocacy campaigns (#WirForschenWeiter), dialogue platforms (Salon Santé), and publishes industry-specific reports on the pharmaceutical sector's economic contribution and animal welfare practices. Interpharma represents member companies including Roche, Novartis, Johnson & Johnson, Pfizer, and others operating at 47 sites across Switzerland.

Differentiator

Problem solved

Functional benefit

Products and services

• Jahresbericht (Annual Report) Annual report providing insights into key metrics, topics and activities of Interpharma, including the relationship between medical progress, supply security and economic strength in Switzerland.
• Innovationsreport (Innovation Report) Annual publication showing the latest drug approvals in Switzerland, current research priorities and the concrete benefits of innovative therapies for patients and the healthcare system.
• Panorama Gesundheit Publication covering health-related topics and analysis of the Swiss healthcare system.
• Pharmastandort Schweiz (Swiss Pharmaceutical Hub Reports) Economic analysis reports on the Swiss pharmaceutical industry's contribution to the national economy, including regional analyses for Basel, Zurich, Zug and Luzern.
• Newsletter Email-based newsletter providing updates on pharmaceutical industry news, policy issues and Interpharma activities.
• biotechlerncenter Online learning center providing biotechnology education and resources.
• Bio-App Mobile application for biotechnology learning and education.
• Datacenter Online portal providing data and statistics about the Swiss pharmaceutical industry.
• Animal Welfare Report Report on Interpharma's commitment to animal welfare, focusing on the 3R principles: replace, reduce and refine animal testing.
• Salon Santé Dialogue platform bringing together politics, science and healthcare stakeholders.
• #WirForschenWeiter (#WeKeepResearching) Political campaign highlighting the importance of pharmaceutical research for Switzerland.
• Medizin bewegt unser Leben campaign Public awareness campaign 'Medizin bewegt unser Leben' (Medicine moves our lives) highlighting the link between pharmaceutical innovation, patient care and the Swiss economy.

Quantifiable outcome

• Swiss pharmaceutical exports reached CHF 287 billion in 2025, accounting for over half of total Swiss exports
• +2 more outcomes

Named customers10 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Seven partnerships are on record, tiered core and minor.

• scienceindustriescoreStrategic or Co-development Partner · 3 July 2025Interpharma and scienceindustries jointly advocated on the FTA with Mercosur countries, emphasizing the importance of IP protection (WTO-TRIPS) for innovative Swiss industries including pharma, chemistry, and biotechnology.
• Swiss Biotech AssociationcoreStrategic or Co-development Partner · 3 July 2025Together with Swiss Biotech Association, Interpharma took note of the Mercosur FTA conclusion and advocated for effective IP protection standards per WTO-TRIPS rules in the agreement.
• Roche and NovartiscoreStrategic or Co-development PartnerSwitzerland's two largest pharmaceutical companies (Roche and Novartis) committed major US investments ($73 billion combined over five years) to produce drugs on American soil to avert U.S. tariffs. Both companies are Interpharma members.
• Medicines Patent Pool (MPP)minorStrategic or Co-development PartnerInterpharma supports voluntary licensing through trusted intermediaries like the Medicines Patent Pool as a means to increase medicine supply while maintaining quality controls, rather than compulsory licensing.
• Product Development Partnerships (PDPs)minorStrategic or Co-development PartnerInterpharma participates in discussions with Product Development Partnerships on voluntary licensing and technology transfer for diseases affecting low- and middle-income countries.
• United KingdomcoreStrategic or Co-development PartnerUK secured tariff-free access to the US pharmaceutical market by agreeing to higher prices for new drugs purchased through the National Health Service. Interpharma urged Swiss government to seek a similar deal.
• Germany (reference for Section 301 probe)minorOthersGermany was already subject to a Section 301 trade investigation initiated by the US. Switzerland was identified as a potential next target for similar action.

Scale indicators12 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• BIO (Biotechnology Innovation Organization): BIO is the world's largest biotech trade association, broader in scope than Interpharma (covering all biotech rather than just research-based pharma). Comparable as a trade body advocating on policy, IP, and market access.

Direct peers

• scienceindustries: scienceindustries is the Swiss business association for chemistry, pharma, and life sciences. Directly comparable as a Swiss trade body — and an active Interpharma partner on FTA/IP advocacy (e.g., Mercosur).
• IFPMA (International Federation of Pharmaceutical Manufacturers and Associations): IFPMA is the global pharma industry association, of which Interpharma is a member association. Closely comparable as a trade body advocating on cross-border pharma policy, IP protection, market access, and global health partnerships.
• PhRMA (Pharmaceutical Research and Manufacturers of America): PhRMA is the US pharma industry association representing leading research-based biopharmaceutical companies. Functionally identical to Interpharma in member-funded advocacy, policy campaigns, and PR on pricing, IP, and trade — making it a direct peer despite geographic difference.
• Swiss Biotech Association: Swiss Biotech Association represents biotechnology companies in Switzerland. Directly comparable as a Swiss-based industry association already partnering with Interpharma on IP/TRIPS advocacy, with overlapping but distinct membership (biotech vs. large-pharma).
• EFPIA (European Federation of Pharmaceutical Industries and Associations): EFPIA is the European-level pharma industry association representing research-based pharma companies. Directly comparable to Interpharma as a trade body performing advocacy, policy engagement, and market-access work for member pharma companies — just at pan-European rather than Swiss national level.
• VFA (Verband der forschenden Pharma-Unternehmen, Germany): VFA is the German association of research-based pharmaceutical companies — the closest direct functional peer to Interpharma, performing the same advocacy, market-access, and policy work for a parallel set of multinational pharma members.

Others

• Medicines Patent Pool (MPP): MPP is a UN-backed public-health organization that negotiates voluntary licenses for medicines. Interpharma engages with MPP as a partner on voluntary licensing — making it a relevant ecosystem peer in the IP/access debate rather than a direct competitor.

Regional players

• Japan Pharmaceutical Manufacturers Association (JPMA): JPMA represents research-based pharma companies in Japan. Comparable as a national pharma industry association with similar advocacy and market-access mandates, though operating in a different regulatory and geographic context.
• BPI (Bundesverband der Pharmazeutischen Industrie, Germany): BPI is the German pharmaceutical industry association. Comparable as a national pharma trade body in a neighboring country that Interpharma frequently benchmarks itself against (e.g., on patient access to innovative medicines).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/interpharma_ch
• Facebookfacebook.com/interpharma.ch
• LinkedInlinkedin.com/company/interpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Interpharma